Chronic kidney disease (CKD) is characterised by an increasing prevalence, with the current prevalence of approximately 10 % in adults > 20 years in Western industrialized countries. In patients with CKD, frequently both the central nervous system (CNS) and the peripheral nervous system (PNS) are affected. Uremia, accumulation of AGE and oxidative stress, hyperkalemia, insulin resistance, adipocytokines, and erythropoietin deficiency and resistance have been identified as potential triggering factors. An impaired cerebral cognitive function in uremic patients is demonstrable even in clinically asymptomatic stages. Typical neurological sequelae include, among others, uremic encephalopathy, dialysis disequilibrium syndrome, and uremic polyneuropathy. In general, initiation of renal replacement treatment is suggested as the most promising therapeutic approach. Additionally, symptomatic treatment of neuropathic pain with first line drugs, such as gabapentin, pregabalin, tricyclic antidepressants or duloxetine, remains a reasonable approach. With respect to the important role of inflammation and oxidative stress in the further deterioration of renal function and nervous damage, additional treatment with benfotiamine may be considered as a pathogenesis-oriented approach.

Wittmann, I., Stirban, A., Tesfaye, S., Gurieva, I., Czupryniak, L., Mankovsky, B., et al. (2015). Neuropathy in chronic kidney disease. DIABETES, STOFFWECHSEL UND HERZ, 24(4), 251-255.

Neuropathy in chronic kidney disease

SPALLONE, VINCENZA;
2015-08-01

Abstract

Chronic kidney disease (CKD) is characterised by an increasing prevalence, with the current prevalence of approximately 10 % in adults > 20 years in Western industrialized countries. In patients with CKD, frequently both the central nervous system (CNS) and the peripheral nervous system (PNS) are affected. Uremia, accumulation of AGE and oxidative stress, hyperkalemia, insulin resistance, adipocytokines, and erythropoietin deficiency and resistance have been identified as potential triggering factors. An impaired cerebral cognitive function in uremic patients is demonstrable even in clinically asymptomatic stages. Typical neurological sequelae include, among others, uremic encephalopathy, dialysis disequilibrium syndrome, and uremic polyneuropathy. In general, initiation of renal replacement treatment is suggested as the most promising therapeutic approach. Additionally, symptomatic treatment of neuropathic pain with first line drugs, such as gabapentin, pregabalin, tricyclic antidepressants or duloxetine, remains a reasonable approach. With respect to the important role of inflammation and oxidative stress in the further deterioration of renal function and nervous damage, additional treatment with benfotiamine may be considered as a pathogenesis-oriented approach.
1-ago-2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/13 - ENDOCRINOLOGIA
English
Con Impact Factor ISI
Diabetes, chronic kidney disease, neuropathy
Wittmann, I., Stirban, A., Tesfaye, S., Gurieva, I., Czupryniak, L., Mankovsky, B., et al. (2015). Neuropathy in chronic kidney disease. DIABETES, STOFFWECHSEL UND HERZ, 24(4), 251-255.
Wittmann, I; Stirban, A; Tesfaye, S; Gurieva, I; Czupryniak, L; Mankovsky, B; Spallone, V; Veresiu, I; Schnell, O; Ziegler, D; Molnar, G; Erbach, M; Kempler, P
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Wittmann_2015_neuropathy in CKD.pdf

solo utenti autorizzati

Descrizione: Articolo
Licenza: Non specificato
Dimensione 1.4 MB
Formato Adobe PDF
1.4 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/151527
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact